APA

Belshe R. B., Clements M. L., Dolin R., Graham B. S., McElrath J., Gorse G. J., Schwartz D., Keefer M. C., Wright P. & Corey L. (19931228). Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. : The Journal of infectious diseases.

Chicago

Belshe R B, Clements M L, Dolin R, Graham B S, McElrath J, Gorse G J, Schwartz D, Keefer M C, Wright P and Corey L. 19931228. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. : The Journal of infectious diseases.

Harvard

Belshe R. B., Clements M. L., Dolin R., Graham B. S., McElrath J., Gorse G. J., Schwartz D., Keefer M. C., Wright P. and Corey L. (19931228). Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. : The Journal of infectious diseases.

MLA

Belshe R B, Clements M L, Dolin R, Graham B S, McElrath J, Gorse G J, Schwartz D, Keefer M C, Wright P and Corey L. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. : The Journal of infectious diseases. 19931228.